Next Article in Journal
Sleep after Heavy Alcohol Consumption and Physical Activity Levels during Alcohol Hangover
Next Article in Special Issue
The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis
Previous Article in Journal
Molecular Genetics and Interferon Signature in the Italian Aicardi Goutières Syndrome Cohort: Report of 12 New Cases and Literature Review
Previous Article in Special Issue
Periodontal Health and Oral Microbiota in Patients with Rheumatoid Arthritis
Article

Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients

1
GIMAP EA3064, Laboratory of Immunology and Immunomonitoring, CIC CIE3 Inserm Vaccinology, Hôpital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, France
2
Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, 31400 Toulouse, France
3
Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, CHU Lyon, 69003 Lyon, France
4
Department of Rheumatology, CHU Grenoble, 38130 Échirolles, France
5
Faculty of Odontology, University Lyon I., 69622 Villeurbanne, France
6
Department of Gastroenterology, Hôpital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, France
7
Department of Rheumatology, Hôpital Nord, CHU Saint-Etienne, 42055 Saint-Etienne, France
8
INSERM U1059, Université de Lyon–Université Jean Monnet, 42023 Saint-Etienne, France
*
Author to whom correspondence should be addressed.
These authors contribute equally to this work.
J. Clin. Med. 2019, 8(5), 751; https://doi.org/10.3390/jcm8050751
Received: 5 April 2019 / Revised: 21 May 2019 / Accepted: 23 May 2019 / Published: 26 May 2019
Objective: Rheumatoid arthritis and periodontal disease are associated together, but the effect of therapy provided for one disease to the second one remained under-investigated. This study investigated effect of infliximab therapy used to treat rheumatoid arthritis (RA) on various biomarkers of periodontal disease (PD) severity including serologies of Porphyromonas gingivalis and Prevotella intermedia and matrix metalloproteinase 3. Methods: Seventy nine RA patients were enrolled at the time to start infliximab therapy and the 28 joint disease activity score (DAS28), anti-cyclic citrullinated petides 2nd generation (anti-CCP2), anti-P. gingivalis antibody, and Matrix metalloproteinase 3 (MMP-3) were monitored before and at 6 months of infliximab therapy. Joint damage and severe periodontal disease were assessed at baseline. Anti-CCP2, anti-P. gingivalis antibody, and MMP-3 were determined by enzyme-linked immunosorbent assay (ELISA). Results: At baseline, anti-CCP2 titers were associated with anti-P. gingivalis lipopolysaccharide (LPS)-specific antibodies titers (p < 0.05). Anti-P. gingivalis antibodies were not significantly correlated with clinical, biological, or destruction parameters of RA disease. At 6 months of infliximab therapy, MMP-3 level decreased (from 119 ± 103 ng/mL to 62.44 ± 52 ng/mL; p < 0.0001), whereas P. gingivalis antibody levels remained at the same level. DAS28 and inflammation markers C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) also decreased significantly during infliximab therapy (p < 0.05) as anti-CCP2 levels (p < 0.001). Only high MMP-3 level at baseline was associated with infliximab efficacy (p < 0.01). Conclusion: MMP-3 level can be a useful marker of the efficacy of infliximab in RA patients. The treatment did not affect anti-P. gingivalis antibodies. View Full-Text
Keywords: Rheumatoid arthritis; Porphyromonas gingivalis; periodontal disease; matrix metalloproteinase 3; infliximab Rheumatoid arthritis; Porphyromonas gingivalis; periodontal disease; matrix metalloproteinase 3; infliximab
Show Figures

Figure 1

MDPI and ACS Style

Rinaudo-Gaujous, M.; Blasco-Baque, V.; Miossec, P.; Gaudin, P.; Farge, P.; Roblin, X.; Thomas, T.; Paul, S.; Marotte, H. Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients. J. Clin. Med. 2019, 8, 751. https://doi.org/10.3390/jcm8050751

AMA Style

Rinaudo-Gaujous M, Blasco-Baque V, Miossec P, Gaudin P, Farge P, Roblin X, Thomas T, Paul S, Marotte H. Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients. Journal of Clinical Medicine. 2019; 8(5):751. https://doi.org/10.3390/jcm8050751

Chicago/Turabian Style

Rinaudo-Gaujous, Mélanie, Vincent Blasco-Baque, Pierre Miossec, Philippe Gaudin, Pierre Farge, Xavier Roblin, Thierry Thomas, Stephane Paul, and Hubert Marotte. 2019. "Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients" Journal of Clinical Medicine 8, no. 5: 751. https://doi.org/10.3390/jcm8050751

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop